BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32350520)

  • 1. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
    Fagnan A; Bagger FO; Piqué-Borràs MR; Ignacimouttou C; Caulier A; Lopez CK; Robert E; Uzan B; Gelsi-Boyer V; Aid Z; Thirant C; Moll U; Tauchmann S; Kurtovic-Kozaric A; Maciejewski J; Dierks C; Spinelli O; Salmoiraghi S; Pabst T; Shimoda K; Deleuze V; Lapillonne H; Sweeney C; De Mas V; Leite B; Kadri Z; Malinge S; de Botton S; Micol JB; Kile B; Carmichael CL; Iacobucci I; Mullighan CG; Carroll M; Valent P; Bernard OA; Delabesse E; Vyas P; Birnbaum D; Anguita E; Garçon L; Soler E; Schwaller J; Mercher T
    Blood; 2020 Aug; 136(6):698-714. PubMed ID: 32350520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.
    Di Genua C; Valletta S; Buono M; Stoilova B; Sweeney C; Rodriguez-Meira A; Grover A; Drissen R; Meng Y; Beveridge R; Aboukhalil Z; Karamitros D; Belderbos ME; Bystrykh L; Thongjuea S; Vyas P; Nerlov C
    Cancer Cell; 2020 May; 37(5):690-704.e8. PubMed ID: 32330454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia.
    Leonards K; Almosailleakh M; Tauchmann S; Bagger FO; Thirant C; Juge S; Bock T; Méreau H; Bezerra MF; Tzankov A; Ivanek R; Losson R; Peters AHFM; Mercher T; Schwaller J
    Nat Commun; 2020 Jun; 11(1):2807. PubMed ID: 32533074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and targeting of erythroleukemia by hematopoietic genome editing.
    Iacobucci I; Qu C; Varotto E; Janke LJ; Yang X; Seth A; Shelat A; Friske JD; Fukano R; Yu J; Freeman BB; Kennedy JA; Sperling AS; Zheng R; Wang Y; Jogiraju H; Dickerson KM; Payne-Turner D; Morris SM; Hollis ES; Ghosn N; Haggard GE; Lindsley RC; Ebert BL; Mullighan CG
    Blood; 2021 Mar; 137(12):1628-1640. PubMed ID: 33512458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
    Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
    Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kunimoto H; McKenney AS; Meydan C; Shank K; Nazir A; Rapaport F; Durham B; Garrett-Bakelman FE; Pronier E; Shih AH; Melnick A; Chaudhuri J; Levine RL
    Blood; 2017 Mar; 129(13):1779-1790. PubMed ID: 28077417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To bi or not to bi: Acute erythroid leukemias and hematopoietic lineage choice.
    Di Genua C; Nerlov C
    Exp Hematol; 2021 May; 97():6-13. PubMed ID: 33600869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular pathogenesis and therapeutic targets in acute erythroid leukemia].
    Takeda J
    Rinsho Ketsueki; 2022; 63(2):121-133. PubMed ID: 35264503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future.
    Liao Z; Li J; Wu J; Liu J; Sun S
    Curr Mol Med; 2021; 21(10):819-831. PubMed ID: 33475071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
    Sportoletti P; Sorcini D; Guzman AG; Reyes JM; Stella A; Marra A; Sartori S; Brunetti L; Rossi R; Papa BD; Adamo FM; Pianigiani G; Betti C; Scialdone A; Guarente V; Spinozzi G; Tini V; Martelli MP; Goodell MA; Falini B
    Leukemia; 2021 Jul; 35(7):1949-1963. PubMed ID: 33159179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.
    Shimamoto T; Ohyashiki K; Ohyashiki JH; Kawakubo K; Fujimura T; Iwama H; Nakazawa S; Toyama K
    Blood; 1995 Oct; 86(8):3173-80. PubMed ID: 7579412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia.
    Takeda J; Yoshida K; Nakagawa MM; Nannya Y; Yoda A; Saiki R; Ochi Y; Zhao L; Okuda R; Qi X; Mori T; Kon A; Chiba K; Tanaka H; Shiraishi Y; Kuo MC; Kerr CM; Nagata Y; Morishita D; Hiramoto N; Hangaishi A; Nakazawa H; Ishiyama K; Miyano S; Chiba S; Miyazaki Y; Kitano T; Usuki K; Sezaki N; Tsurumi H; Miyawaki S; Maciejewski JP; Ishikawa T; Ohyashiki K; Ganser A; Heuser M; Thol F; Shih LY; Takaori-Kondo A; Makishima H; Ogawa S
    Blood Cancer Discov; 2022 Sep; 3(5):410-427. PubMed ID: 35839275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute erythroid leukemia.
    Zuo Z; Polski JM; Kasyan A; Medeiros LJ
    Arch Pathol Lab Med; 2010 Sep; 134(9):1261-70. PubMed ID: 20807044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF).
    Maag AH; Swanton H; Kull M; Vegi NM; Feuring M
    Cytometry A; 2023 Jul; 103(7):551-562. PubMed ID: 36647792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
    Stankiewicz MJ; Crispino JD
    Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis.
    Maeda T; Ito K; Merghoub T; Poliseno L; Hobbs RM; Wang G; Dong L; Maeda M; Dore LC; Zelent A; Luzzatto L; Teruya-Feldstein J; Weiss MJ; Pandolfi PP
    Dev Cell; 2009 Oct; 17(4):527-40. PubMed ID: 19853566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia.
    Liu W; Wu Z; Yu Y; Qiao C; Zhu H; Hong M; Zhu Y; Qian S; Chen S; Wu D; Li J; Jin H
    Oxid Med Cell Longev; 2022; 2022():5885342. PubMed ID: 35140839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translocation 21;22 may be involved in control of differentiation in erythroleukemia.
    Fujisawa S; Motomura S; Fujimaki K; Okubo T
    Am J Hematol; 1996 May; 52(1):65. PubMed ID: 8638620
    [No Abstract]   [Full Text] [Related]  

  • 20. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα.
    Kohrogi K; Hino S; Sakamoto A; Anan K; Takase R; Araki H; Hino Y; Araki K; Sato T; Nakamura K; Nakao M
    Blood Adv; 2021 May; 5(9):2305-2318. PubMed ID: 33929501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.